April 17, 2017 / 12:08 PM / in 8 months

BRIEF-Janssen receives Health Canada approval of Darzalex by priority review

April 17 (Reuters) - Johnson & Johnson

* Receives Health Canada approval of Darzalex® (daratumumab) by priority review for patients with multiple myeloma who have had at least one prior therapy

* Janssen Inc - data from two Phase 3 studies supported new approval of darzalex

* Janssen Inc - due to “high” unmet medical need for multiple myeloma patients, darzalex was granted priority review by Health Canada for submission Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below